Astrazeneca plc - ADR (AZN) Company Profile & Statistics

Astrazeneca plc - ADR
AZN
(Nasdaq - US)
Closed
63.22
-1.82 (-2.80%)
in:usd•As of: Nov 15, 2024 15:59 UTC -5
After Market:63.31+0.09 (+0.14%)
Open
63.82
High
64.03
Low
63.17

About Astrazeneca plc - ADR

CEO

Pascal Soriot

Headquarters

1 francis crick avenue, cambridge biomedical campus

cambridge, x0 cb2 0aa, united kingdom

Auditor

PricewaterhouseCoopers LLP

Employees

89,900

Share Holders

N/A

Website

www.astrazeneca.com

Industry

pharmaceuticals major

Sector

health technology

Company Overview

AstraZeneca plc, is one of the largest biopharmaceutical companies in the world. AstraZeneca's business can be broken down into separate lines based on therapeutic classes. These include cardiovascular, respiratory, immunology, oncology, rare diseases and other.In July 2021 AstraZeneca closed the acquisition of rare disease drugmaker, Alexion. The acquisition added Alexion's five marketed rare disease products and its pipeline of immune-mediated rare disease candidates.In order to bolster its respiratory portfolio, AstraZeneca acquired rights to Allergan's branded respiratory business in the U.S. and Canada in Mar 2015. The company also acquired Takeda's core respiratory business in May 2016.In June 2007, AstraZeneca acquired biotechnology company MedImmune. In Aug 2011, AstraZeneca sold its Astra Tech business to DENTSPLY. AstraZeneca entered into a number of deals and struck agreements with companies such as FibroGen and Daiichi Sankyo.

Astrazeneca plc - ADR Statistics

Valuation Measures

Market Capitalization ²	196.02B
Enterprise Value	221.40B
Enterprise Value/EBITDA (ttm)	15.60
Price to Earnings Ratio (ttm)	16.68
Price to Book (mrq)	4.80
Price to Sales (ttm)	3.83
Price to Cash (ytd)	11.72

Profitability

Gross Margin (ttm)	82.05%
Operating Margin (ttm)	23.01%
Profit Margin (ttm)	13.00%
Return on Equity (ttm)	30.01%
Return on Invested Capital (ttm)	10.13%
Return on Assets (ttm)	11.42%

Income Statement

Revenue (ttm)	49.13B
Revenue Per Share (ttm)	N/A
Gross Profit (ttm)	40.33B
EBITDA (ttm)³	14.19B
Net Income Avi to Common (ttm)	6.44B
Diluted EPS (ttm)	2.09

Share Statistics

Beta (5Y Monthly)	0.47
52-Week Change	1.25%
S&P500 52-Week Change	29.10%
S&P500 Member	No
Stock Optionable	Yes
Total Shares Outstanding ¹	N/A
Dividend Yield	1.55%
Float ⁴	0.00
% Held by Insiders	N/A
% Held by Institutions	20.35%

Balance Sheet

Total Cash (mrq)	7.10B
Total Cash Per Share (mrq)	N/A
Total Debt (mrq)	32.29B
Total Debt/Equity (mrq)	81.55%
Current Ratio (mrq)	0.89%
Quick Ratio (mrq)	0.69%
Book Value Per Share (mrq)	N/A

Cash Flow

Operating Cash Flow Per Share (ytd)	1.79
Free Cash Flow (ytd)	4.83B

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.

¹ Total Shares outstanding is taken from the most recently filed quarterly or annual report.

² Market Cap is calculated using total shares outstanding and the most recent share price.

³ EBITDA is calculated using methodology that may differ from that used by a company in its reporting.

⁴ The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

Astrazeneca plc - ADR

Trade With A Regulated Broker